7.98
+0.08(+1.01%)
Currency In USD
| Previous Close | 7.9 |
| Open | 7.9 |
| Day High | 8.03 |
| Day Low | 7.76 |
| 52-Week High | 14.42 |
| 52-Week Low | 6.11 |
| Volume | 76,969 |
| Average Volume | 78,312 |
| Market Cap | 724.95M |
| PE | 199.5 |
| EPS | 0.04 |
| Moving Average 50 Days | 7.78 |
| Moving Average 200 Days | 8.39 |
| Change | 0.08 |
If you invested $1000 in Gyre Therapeutics, Inc. (GYRE) 10 years ago, it would be worth $14.95 as of December 08, 2025 at a share price of $7.98. Whereas If you bought $1000 worth of Gyre Therapeutics, Inc. (GYRE) shares 5 years ago, it would be worth $93.81 as of December 08, 2025 at a share price of $7.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
GlobeNewswire Inc.
Oct 15, 2025 11:00 AM GMT
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announc
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, toda
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 05, 2025 8:05 PM GMT
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, tod